Literature DB >> 18521374

Metastatic secondary fibrosarcoma of bone responsive to repeated courses of Ifosfamide and associated with hypoglycemia.

Elaine S Bouttell1, N Wilson Rodger, Vivien H C Bramwell.   

Abstract

We present a case of a 40-year-old man with secondary fibrosarcoma of bone, arising from a non-ossifying fibroma. He subsequently developed metastatic disease that responded to four successive chemotherapy courses, the last three using the same dose/schedule of single agent ifosfamide. Eventual rapid progression of a huge intra-abdominal mass was associated with the syndrome of extrapancreatic tumour hypoglycemia (EPTH). The clinicopathological behaviour of fibrosarcoma of bone, and the mechanism of EPTH are discussed.

Entities:  

Year:  2003        PMID: 18521374      PMCID: PMC2395515          DOI: 10.1080/13577140310001607329

Source DB:  PubMed          Journal:  Sarcoma        ISSN: 1357-714X


  26 in total

1.  Insulin-like growth factors I and II in healthy man. Estimations of half-lives and production rates.

Authors:  H P Guler; J Zapf; C Schmid; E R Froesch
Journal:  Acta Endocrinol (Copenh)       Date:  1989-12

2.  Successful treatment of hypoglycemia using glucagon in a patient with an extrapancreatic tumor.

Authors:  N A Samaan; F K Pham; R V Sellin; J F Fernandez; R S Benjamin
Journal:  Ann Intern Med       Date:  1990-09-01       Impact factor: 25.391

3.  FIBRO-SARCOMA OF THE MEDIASTINUM.

Authors:  K W Doege
Journal:  Ann Surg       Date:  1930-11       Impact factor: 12.969

4.  Neoadjuvant chemotherapy with doxorubicin and cisplatin in malignant fibrous histiocytoma of bone: A European Osteosarcoma Intergroup study.

Authors:  V H Bramwell; W P Steward; M Nooij; J Whelan; A W Craft; R J Grimer; A H Taminau; S R Cannon; A J Malcolm; P C Hogendoorn; B Uscinska; A L Kirkpatrick; D Machin; M M Van Glabbeke
Journal:  J Clin Oncol       Date:  1999-10       Impact factor: 44.544

5.  Insulin-like growth factor-II in nonislet cell tumors associated with hypoglycemia: increased levels of messenger ribonucleic acid.

Authors:  W L Lowe; C T Roberts; D LeRoith; M T Rojeski; T J Merimee; S T Fui; H Keen; D Arnold; J Mersey; S Gluzman
Journal:  J Clin Endocrinol Metab       Date:  1989-12       Impact factor: 5.958

6.  Primary fibrosarcoma of bone. Outcome after primary surgical treatment.

Authors:  P J Papagelopoulos; E Galanis; F J Frassica; F H Sim; D R Larson; L E Wold
Journal:  Clin Orthop Relat Res       Date:  2000-04       Impact factor: 4.176

Review 7.  Soft tissue fibrosarcoma. A clinicopathologic study of 132 cases.

Authors:  S M Scott; H M Reiman; D J Pritchard; D M Ilstrup
Journal:  Cancer       Date:  1989-08-15       Impact factor: 6.860

8.  Significance of abnormal serum binding of insulin-like growth factor II in the development of hypoglycemia in patients with non-islet-cell tumors.

Authors:  W H Daughaday; M Kapadia
Journal:  Proc Natl Acad Sci U S A       Date:  1989-09       Impact factor: 11.205

9.  Primary fibrosarcoma of bone. A clinicopathologic study of 130 patients.

Authors:  A G Huvos; N L Higinbotham
Journal:  Cancer       Date:  1975-03       Impact factor: 6.860

10.  Doxorubicin-based chemotherapy for the palliative treatment of adult patients with locally advanced or metastatic soft-tissue sarcoma: a meta-analysis and clinical practice guideline.

Authors:  V H Bramwell; D Anderson; M L Charette
Journal:  Sarcoma       Date:  2000
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.